Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

More than 49,000 people in the US have filled prescriptions for Truvada for PrEP at retail pharmacies, according to the results of a survey by Gilead Sciences. Among PrEP users with available data, most were white gay men. Black people used PrEP much less often, despite having the highest rates of HIV infection.

June 22, 2016

An aidsmap summary of additional data from the Partners PrEP trial in serodiscordant couples showing that intimate partner violence affects adherence—a finding that also exists for people taking ART as HIV treatment.

June 20, 2016

Shannon Weber, director of HIVE, and Dominka Seidman MD, of the University of California San Franciso, argue in the Huffington Post that the best way to rollout PrEP to women is through a shared decision-making approach, allowing patients and providers to make health care decision together, taking into account the best scientific evidence available, along with the patient's experiences, values and preferences.

June 17, 2016
The Huffington Post
Subscribe to RSS - PrEP